Form SCHEDULE 13G NEUROCRINE BIOSCIENCES Filed by: STATE STREET CORP
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Qualcomm to issue warrant to Amazon for up to 25M shares
- Trump says Canada's Bombardier must build jets in US or lose market access
- Wall St slips as Gulf tensions send oil to over six-week high
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Neurocrine Bio. (NBIX) PT Lowered to $179 at BofA Securities
February 7, 2025 6:08 AM ESTBofA Securities analyst Tazeen Ahmad lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $179.00 (from $184.00) while maintaining a Buy rating.
The analyst comments "NBIX announced FY24 Ingrezza revenues of $2.31bn (+26% y/y, ours: $2.316bn, cons: $2.32bn). On FY25 outlook, the company guided to FY25 sales of... More
